What Does the Study Involve?
The first part of the study is a single visit where you will get an HIV test and other lab tests.
If you do not have HIV and meet the other eligibility criteria, you can choose to participate in the second part of the study.
If you are confirmed to have HIV, we will link you to HIV care in your community.
Everyone who enrolls in the second part of the study will
receive a daily pill and an injection given every 6 months.
Of the injection and the pill, one will be the active drug and one will be a placebo.
The second part of the study will last for at least 1 year and up to 3 years.
The visits are 4-13 weeks apart, with 4-8 visits per year.
- Which drug you receive will be determined by chance
- The active drug you receive may be lenacapavir (2 out of 3 chance) or F/TDF (1 out of 3 chance)
- Neither you nor the study doctor will know which medication is active and which is placebo
- When the first part of the study is over, you will find out which active drug you were taking, and you may have the option to enroll in an extension phase where everyone receives lenacapavir
More information about the PURPOSE 2
study can also be found at clinicaltrials.gov.